

MYERS BIGEL SIBLEY & SAJOVEC
Patent Attorneys
4140 Parklake Avenue, Suite 600, Raleigh, NC 27612
P.O. Box 37428, Raleigh, NC 27627
Telephone 919-854-1400
Facsimile 919-854-1401

RECEIVED
CENTRAL FAX CENTER

NOV 07 2005

TELECOPIER TRANSMISSION
COVER SHEET

CERTIFICATE OF FACSIMILE TRANSMISSION
UNDER 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office for Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2213-1450 on November 7, 2005 via facsimile number (571) 273-8300.


Signature

Tracy Wallace
Typed or Printed Name of Person Signing Certificate

Attorney Docket No.9237.23

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ahuja et al.
Serial No.: 10/089,595
International Filing Date: October 12, 2000
For: Screening for Disease Susceptibility by Genotyping the CCR2 Genes
Submittal of:

Cover page (1 page)
Second Preliminary Amendment (8 pages)

Confidentiality Note

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby prohibited. If you have received this telecopy in error, please immediately notify us by telephone and return the original message to us at the address above via the United States Postal Service. THANK YOU.

NOV. 7. 2005 10:31AM

919-854-1401 MBS&S

NO. 2159 P. 2/9

**RECEIVED
CENTRAL FAX CENTER**

NOV 07 2005

Attorney Docket No. 9237.23

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ahuja et al.

Confirmation No.: 2489

Application Serial No.: 10/089,595

International Filing Date: October 12, 2000

For: *Screening for Disease Susceptibility by Genotyping the CCR5 and CCR2 Genes*

November 7, 2005

Via Facsimile Transmission 571-273-8300

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SECOND PRELIMINARY AMENDMENT

Before any action on the merits is taken regarding the above-identified patent application, please enter the following amendments and consider the following remarks.